2021 AACR: Profiling tumor-infiltrating immune cells using an augmented transcriptome Due to the complexity of tumor-immune interactions, comprehensive profiling of both the tumor and tumor microenvironment (TME) can help further our understanding of tumor progression and response to treatment. One significant application is quantification of the immune infiltrate, which has the potential to characterize [...]
Our CAP-accredited, CLIA-certified laboratory operates 7 days a week and is one of the largest sequencing centers in the U.S. today with a capacity to sequence >100,000 human whole genome/exome scale samples per year. Our lab boasts the latest in technology to ensure high quality data delivery and rapid timelines, including: [...]
Provider FAQs for NeXT Dx™ Test This document covers Provider FAQs and cancer genes of clinical importance covered by the Personalis NeXT Dx™ Test.
2020 EACR Liquid Biopsies Sponsored Symposia NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics Erin Newburn, PhD Associate Director, Field Applications Scientist Dan Norton, MBA Sr. Product Manager NeXT Liquid Biopsy™, a first-of-its-kind, high-performance exome-wide [...]
2020 SITC: Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity T cells can inhibit tumor growth and progression by recognizing major histocompatibility complex class I (MHC-I) -bound peptides derived from antigens that are mutated, inappropriately expressed, or overexpressed in the tumor cells (vs. healthy cells). There are many mechanisms by which [...]
2020 SITC: B-cell receptor heavy chain repertoire profiling using an augmented transcriptome Comprehensively profiling the tumor and tumor microenvironment (TME) can help provide a more complete view of the complex interactions between the tumor and immune system, potentially furthering our understanding of tumor progression and response to treatment. We have developed an augmented, immuno-oncology-optimized exome/transcriptome [...]
2020 SITC: Profiling tumor circulating cell-free DNA with an enhanced whole-exome to enable sensitive assessment of somatic mutations The analysis of tumors using circulating cell-free DNA (cfDNA) is beginning to transform cancer diagnosis, prognosis, response to therapy and to enable disease progression monitoring. Most cfDNA assays are centered around the identification of therapeutically actionable [...]
2020 SITC: Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Our ImmunoID NeXT™ Platform enables a [...]
2020 AMP: An exome and transcriptome based NeXT Dx™ test enables therapy selection for cancer patients and offers insight into emerging composite biomarkers for immunotherapy The emergence of immune checkpoint inhibitors has highlighted the potential of immuno-oncology therapeutics to produce unprecedented beneficial responses in cancer patients. However, diagnostic biomarkers that consistently predict patient response [...]
2020 EACR Liquid Biopsies: Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach The analysis of tumors using circulating cell-free DNA (cfDNA) is beginning to transform cancer diagnosis, prognosis, response to therapy and to enable disease progression monitoring. Most cfDNA assays are centered around the identification of therapeutically [...]
